<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02252237</url>
  </required_header>
  <id_info>
    <org_study_id>2014-A00987-40</org_study_id>
    <nct_id>NCT02252237</nct_id>
  </id_info>
  <brief_title>Pharmacokinetics of Prednisone, Prednisolone, Methylprednisolone in Children</brief_title>
  <acronym>GLUCOPED</acronym>
  <official_title>Study of Pharmacokinetic Variability of Corticoids (Prednisone, Prednisolone, Methylprednisolone) in Children</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine individual susceptibility factors (drug
      interactions, genetic factors such as enzyme polymorphism…) to explain wide interindividual
      variability towards corticosteroids (prednisone, prednisolone, methylprednisolone) in
      children, which could establish a base for therapeutic monitoring.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Corticosteroids are widely used in children. A large interindividual variability exists
      concerning both efficacity and tolerance. Pharmacokinetic is poorly known.

      A knowledge of individual susceptibility factors would allow to better adapt therapy in each
      case.

      Drugs evaluated here are used in routine care in children and will be prescribed according to
      department practices concerning treated disease. Medical checks will be done during usual
      follow-up. Several features will be collected: reason of treatment, drug chosen and
      prescription modalities, observance, concomitant treatments, side effects, clinical
      examination, photography, score… Blood samples will be performed at different interval during
      usual biological follow-up. Three samples per patient will be required for pharmacokinetic
      and pharmacogenetic.

      115 children under prednisone/prednisolone and 85 under methylprednisolone will be recruited
      in three pediatric medical departments: immuno-hematology, nephrology and dermatology.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">December 3, 2014</start_date>
  <completion_date type="Anticipated">June 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Composite of Pharmacokinetic parameter for Prednisone, Prednisolone, Methylprednisolone</measure>
    <time_frame>24 months</time_frame>
    <description>Assessed by:
Volume of distribution of creatinine
Creatinine clearance</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Side effects</measure>
    <time_frame>24 months</time_frame>
    <description>Ferryman and Gallwey score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Side effects</measure>
    <time_frame>24 months</time_frame>
    <description>Dermaphot® score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Analysis of genetic polymorphism of proteins taking part in glucocorticoids metabolism</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">146</enrollment>
  <condition>Children Receiving Prednisone or Prednisolone or Methylprednisolone</condition>
  <arm_group>
    <arm_group_label>Children with glucocorticoids</arm_group_label>
    <description>Children receiving Prednisone or Prednisolone or Methylprednisolone Pharmacokinetic</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Pharmacokinetic</intervention_name>
    <description>Blood sample of 2 ml at enrolment and then at two following visits. Buccal cell collection swab</description>
    <arm_group_label>Children with glucocorticoids</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Buccal cell collection swab
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Children receiving glucocorticoids (Prednisone or Prednisolone or Methylprednisolone) are
        recruited in Immuno-hematological unit, dermatological unit , in pediatric nephrological
        unit or pediatric intensive care unit
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  receiving Prednisone or Prednisolone or Methylprednisolone

          -  recruited in Immuno-hematological unit, dermatological unit , in pediatric
             nephrological unit or pediatric intensive care unit

          -  parental agreement

        Exclusion Criteria:

          -  parental refusal

          -  inability to take a blood sample

          -  inhaled corticoids intake in the 3 previous days

          -  topical corticoids intake in the 3 previous days
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jean-Marc Tréluyer, MD-PhD</last_name>
    <role>Study Director</role>
    <affiliation>Assistance Publique - Hôpitaux de Paris</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>AP-HP Necker</name>
      <address>
        <city>Paris</city>
        <zip>75015</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <reference>
    <citation>Bartoszek M, Brenner AM, Szefler SJ. Prednisolone and methylprednisolone kinetics in children receiving anticonvulsant therapy. Clin Pharmacol Ther. 1987 Oct;42(4):424-32.</citation>
    <PMID>3665340</PMID>
  </reference>
  <reference>
    <citation>Hoffmeyer S, Burk O, von Richter O, Arnold HP, Brockmöller J, Johne A, Cascorbi I, Gerloff T, Roots I, Eichelbaum M, Brinkmann U. Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci U S A. 2000 Mar 28;97(7):3473-8.</citation>
    <PMID>10716719</PMID>
  </reference>
  <reference>
    <citation>Jamroziak K, Młynarski W, Balcerczak E, Mistygacz M, Trelinska J, Mirowski M, Bodalski J, Robak T. Functional C3435T polymorphism of MDR1 gene: an impact on genetic susceptibility and clinical outcome of childhood acute lymphoblastic leukemia. Eur J Haematol. 2004 May;72(5):314-21.</citation>
    <PMID>15059065</PMID>
  </reference>
  <reference>
    <citation>Gatti G, Perucca E, Frigo GM, Notarangelo LD, Barberis L, Martini A. Pharmacokinetics of prednisone and its metabolite prednisolone in children with nephrotic syndrome during the active phase and in remission. Br J Clin Pharmacol. 1984 Apr;17(4):423-31.</citation>
    <PMID>6721988</PMID>
  </reference>
  <reference>
    <citation>Miller PF, Bowmer CJ, Wheeldon J, Brocklebank JT. Pharmacokinetics of prednisolone in children with nephrosis. Arch Dis Child. 1990 Feb;65(2):196-200.</citation>
    <PMID>2317067</PMID>
  </reference>
  <reference>
    <citation>Petersen KB, Jusko WJ, Rasmussen M, Schmiegelow K. Population pharmacokinetics of prednisolone in children with acute lymphoblastic leukemia. Cancer Chemother Pharmacol. 2003 Jun;51(6):465-73. Epub 2003 Apr 16.</citation>
    <PMID>12698270</PMID>
  </reference>
  <reference>
    <citation>Faure C, André J, Pelatan C, Munck A, Giraud M, Cèzard JP, Jacqz-Aigrain E. Pharmacokinetics of intravenous methylprednisolone and oral prednisone in paediatric patients with inflammatory bowel disease during the acute phase and in remission. Eur J Clin Pharmacol. 1998 Sep;54(7):555-60.</citation>
    <PMID>9832298</PMID>
  </reference>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 26, 2014</study_first_submitted>
  <study_first_submitted_qc>September 29, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 30, 2014</study_first_posted>
  <last_update_submitted>April 13, 2018</last_update_submitted>
  <last_update_submitted_qc>April 13, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 17, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Prednisone</keyword>
  <keyword>Prednisolone</keyword>
  <keyword>Methylprednisolone</keyword>
  <keyword>Glucocorticoids</keyword>
  <keyword>pharmacokinetics</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prednisolone acetate</mesh_term>
    <mesh_term>Methylprednisolone acetate</mesh_term>
    <mesh_term>Prednisone</mesh_term>
    <mesh_term>Prednisolone</mesh_term>
    <mesh_term>Methylprednisolone</mesh_term>
    <mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
    <mesh_term>Prednisolone hemisuccinate</mesh_term>
    <mesh_term>Prednisolone phosphate</mesh_term>
    <mesh_term>Glucocorticoids</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

